Skip to main content
OpenTrials
Completed

NCT Number: NCT04126759

Calibration of a Non-invasive Glucose Measurement Device and Assessment of Its Performance in the Hypoglycemic Range in Patients With Type 1 Diabetes

This clinical study has been launched to collect spectral Raman data and reference measurements to establish and validate a calibration model for the device during daily glycemic fluctuations and evaluate analytical performance of device in the hypoglycemic range. The study is a combined home-based and in-clinic study where subjects will attend the clinic two times.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center Copenhagen (SDCC)

Gentofte Municipality, 2820, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female subjects between 18 and 40 years of age.
  • Diagnosed with type 1 diabetes mellitus.
  • Uses an insulin pen or pump.
  • Hb1Ac > 55 mmol/mol at baseline visit.
  • Skin phototype 1-4 according to Fitzpatrick skin tone scale.
  • Willing to perform a minimum of 8 finger sticks per day during the study for the home-based study and approximately 16 finger sticks for the in-clinic study days.
  • Willing to have a peripheral venous catheter inserted.
  • Willing to provide written signed and dated informed consent.

Exclusion criteria

  • Breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control according to approved contraceptives from NCA during the study execution (applicable to female subjects only).
  • Subjects not able to understand and read Danish.
  • Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator.
  • Subject is not able to hold hand/arm steadily (including tremors and Parkinson's Disease).
  • Reduced circulation in hand. "Allen's test" is used for assessing hand circulation to evaluate occurrence of reduced blood.
  • Extensive skin changes, tattoos or diseases on probe application site (thenar) that could interfere with the accuracy of the interstitial glucose measurements.
  • Known allergy to medical grade alcohol.
  • Having active cancer treatment and/or use tetracyclines and other medication / topical agents known to increase photosensitivity in skin.
  • Medical history or any condition that may, in the opinion of the Investigator, compromise the subject's ability to participate
  • Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff.
  • Diagnosed with cardiovascular diseases.
  • Subjects currently enrolled in another study.
  • Radiotherapy for the past six months.

Treatment and study plan

P0.3

Device

Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.

Primary outcomes

  1. Generation of predictive algorithms for determining blood glucose levels

    Time frame: 12 months

    Collected spectral raman data will found the development of predictive algorithms for glucose determination.

  2. Validation of predictive algorithms for determining blood glucose levels

    Time frame: 12 months

    Performance of predictive models will be evaluated using the consensus error grid.Unified Performance (ISUP), Mean Absolute Relative Difference (MARD) and Consensus Error Grid (CEG) distribution.

Secondary outcomes

  1. Risk/benefit analysis

    Time frame: 12 months

    Support of a favorable risk/benefit analysis based on reported Adverse Device Effects and Serious Adverse Device Effects.

  2. Number of encountered Device Deficiencies

    Time frame: 12 months

    Evaluation of Device Deficiencies with respect to identity, quality, durability or reliability, including malfunctions, use errors and inadequate labeling.

Sponsors and collaborators

Lead sponsor

RSP Systems A/S

Industry

Collaborators

  • Steno Diabetes Center Copenhagen

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Oct 15, 2019
Registry last updated
Oct 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.